Surgery Partners vs. Viemed Healthcare: Which Outpatient Care Stock Is a Better Buy in 2026?

The article favors Viemed Healthcare over Surgery Partners, citing faster FY2025 revenue growth of 21% to $270.3 million versus 6% growth to just over $3.3 billion for Surgery Partners. Viemed also has stronger profitability and balance sheet metrics, including $14.9 million in net income, 0.1x debt-to-equity, and $11.9 million in free cash flow, while Surgery Partners carried $77.9 million in net loss and about $3.7 billion in debt. The piece highlights regulatory and reimbursement risks for both names, but its overall stance is that Viemed is the better 2026 portfolio choice.

Analysis

The market is implicitly rewarding the business model with the cleaner balance sheet and the faster reimbursement-linked growth curve. VMD’s setup is better because its expansion is less capital intensive, so incremental revenue can translate into operating leverage faster than a facility-heavy model burdened by fixed costs and leverage. In a year where investors are paying up for visible earnings conversion, that matters more than absolute scale.

The second-order effect is that SGRY’s large footprint becomes a liability if volume growth slows even modestly: leveraged healthcare assets tend to de-rate quickly when top-line momentum decelerates, because debt service and compliance costs don’t flex down. By contrast, VMD’s risk is more “policy shock” than “balance-sheet shock,” which is usually easier for the market to underwrite over 6-12 months. The key nuance is that VMD’s concentration in Medicare is a real overhang, but it also creates an asymmetric setup: stable reimbursement or even modest share gains can sustain multiple expansion, while a rate cut would likely be visible early through slower patient acquisition and lower utilization.

Consensus may be underestimating how much the current environment favors asset-light care delivery. If insurers continue steering patients away from institutional settings, the winners are not just direct substitutes like VMD but also equipment suppliers and care-coordination vendors attached to the home-health stack. That creates a broader tradeable basket around the theme, while SGRY remains more of a value trap unless management can prove that growth can outpace leverage and regulatory drag within the next 2-3 quarters.

Key Decisions for Investors

• Long VMD / short SGRY as a 6-12 month pair trade; thesis is faster earnings translation and lower balance-sheet risk for VMD versus de-rating risk in SGRY if growth slips even modestly.
• Add VMD on pullbacks over the next 2-6 weeks; risk/reward favors owning a reimbursement-sensitive growth name with positive operating leverage into the next 1-2 quarters.
• Avoid initiating a fresh outright long in SGRY unless it trades at a materially wider discount to sales and management demonstrates deleveraging progress; current setup has poor convexity for new capital.
• For higher risk tolerance, buy VMD call spreads dated 3-6 months out to express upside from continued share gains while limiting exposure to a Medicare reimbursement surprise.
• If you already own SGRY, use strength to trim or hedge with a short VMD/long SGRY relative-value overlay only if you expect a short-term mean reversion in valuation multiples; otherwise the cleaner path is reducing SGRY exposure.